Identifying Factors Associated with the Efficacy of Lasmiditan 50 mg as an Acute Treatment for Migraine Attacks Under Various Dosing Conditions in Real-World Clinical Practice by Takafumi Tanei, Shun Yamamoto, Satoshi Maesawa, Yusuke Nishimura, Tomotaka Ishizaki, Yoshitaka Nagashima, Yoshiki Ito, Miki Hashida, Takahiro Suzuki, Hajime Hamasaki, Toshihiko Wakabayashi, Ryuta Saito

Subjects: “…lasmiditan…”
Get full text

The Relationship Between Treatment Satisfaction and Medication Understanding Among Patients Taking a Novel Oral Pain Reliever: A Questionnaire-Based Cross-Sectional Study by Makio Takahashi, Sho Kodama, Maiko Akahane, Shuhei Yamamoto, Takashi Yonemoto, Haruhiko Seki

Subjects: “…Lasmiditan…”
Get full text

Efficacy of lasmiditan, rimegepant and ubrogepant for acute treatment of migraine in triptan insufficient responders: systematic review and network meta-analysis by Wattakorn Laohapiboolrattana, Priabprat Jansem, Prakit Anukoolwittaya, Duangnapa Roongpiboonsopit, Akarin Hiransuthikul, Thanakit Pongpitakmetha, Sekh Thanprasertsuk, Wanakorn Rattanawong

Subjects: Get full text

The impact of headache specialist density and the introduction of gepants and lasmitidan on prescriptions for acute migraine treatments: a regression and interrupted time series an... by Leon S. Moskatel, Rebecca Y. Linfield, Niushen Zhang

Subjects: Get full text

Integrative snRNA‐seq, molecular docking and dynamics simulations identifies Lasmiditan as drug candidate for Alzheimer's disease by Martin Nwadiugwu, Md Selim Reza, Boluwatife Afolabi, Demetrius M. Maraganore, Hui Shen, Hongwen Deng

Subjects: Get full text